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Abstract
Immunodominance is a fundamental property of CD8+ T cell responses to viruses and vaccines. It had been observed that
route of administration alters immunodominance after vaccinia virus (VACV) infection, but only a few epitopes were
examined and no mechanism was provided. We re-visited this issue, examining a panel of 15 VACV epitopes and four
routes, namely intradermal (i.d.), subcutaneous (s.c.), intraperitoneal (i.p.) and intravenous (i.v.) injection. We found that
immunodominance is sharpened following peripheral routes of infection (i.d. and s.c.) compared with those that allow
systemic virus dissemination (i.p. and i.v.). This increased immunodominance was demonstrated with native epitopes of
VACV and with herpes simplex virus glycoprotein B when expressed from VACV. Responses to some subdominant epitopes
were altered by as much as fourfold. Tracking of virus, examination of priming sites, and experiments restricting virus spread
showed that priming of CD8+ T cells in the spleen was necessary, but not sufficient to broaden responses. Further, we
directly demonstrated that immunodomination occurs more readily when priming is mainly in lymph nodes. Finally, we
were able to reduce immunodominance after i.d., but not i.p. infection, using a VACV expressing the costimulators CD80
(B7-1) and CD86 (B7-2), which is notable because VACV-based vaccines incorporating these molecules are in clinical trials.
Taken together, our data indicate that resources for CD8+ T cell priming are limiting in local draining lymph nodes, leading
to greater immunodomination. Further, we provide evidence that costimulation can be a limiting factor that contributes to
immunodomination. These results shed light on a possible mechanism of immunodomination and highlight the need to
consider multiple epitopes across the spectrum of immunogenicities in studies aimed at understanding CD8+ T cell
immunity to viruses.
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Introduction
Immunodominance is a term used to describe the preferential
recognition of some epitopes over others in a complex antigen and
is a fundamental property of all immune responses. CD8+ T cell
responses to viruses are no exception and immunodominance has
been noted for many viruses in mice and humans [1,2].
Immunodominance arises due to factors that affect either 1) the
amount of peptide-MHC (pMHC) complexes, including abun-
dance of parent antigen, ease of processing and affinity of peptides
for MHC [3–17] or 2) the quantity or quality of T cells in the
naive repertoire that recognize these pMHC complexes
[5,8,10,11,18–29]. An additional determinant that emerges from
the intersection of the factors above is immunodomination, which
is the ability of T cells with dominant specificities to inhibit
responses to less-dominant epitopes. This is observed most clearly
in secondary infections, where some memory T cells are clearly
less able to compete [30–34]. However, it must also operate in
primary infection, because deletion of immunodominant epitopes
allows responses to subdominant epitopes to increase [10,30,35].
Further in some, but not all cases pre-priming of individual
epitopes can lead to radically altered dominance hierarchies,
presumably because the already primed T cells have an advantage
over other specificities [5,36,37]. Finally, competition amongst the
various clones recognising the same specificity can be directly
observed during infection by monitoring the expansion adoptively
transferred TCR transgenic T cells compared with the endoge-
nous polyclonal response [38]. While the mechanism of immuno-
domination remains obscure, it can be relieved if the epitopes are
presented on separate antigen presenting cells (APCs). Therefore it
is most likely due to competition for resources either on APCs or
released by APCs in the immediate environment, but these remain
undefined [36,38–40].
Vaccinia virus (VACV) was used as the live vaccine to eradicate
smallpox and attenuated strains are now being used as vectors for
recombinant vaccines. In understanding both the historical and
contemporary usage of VACV, CD8+ T cell responses are of
interest. Further, VACV provides an excellent model for studies of
immunodominance because it has a large genome with many
mapped epitopes and infections are entirely acute. These attributes
set it apart from the well-studied RNA viruses such as influenza or
lymphocytic choriomeningitis viruses, with genomes less than a
tenth the size and the herpesviruses, all of which cause latent/
persistent infections. Of the roughly 50 CD8+ T cell epitopes for
VACV identified in the C57BL/6 mouse, B8R20 (TSYKFESV) is
by far the most dominant [41–45]. Depending on the estimate of
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the total anti-VACV CD8+ T cell population, 10–25% of all anti-
viral CD8+ T cells are specific for this epitope during acute
infection and we refer to this as the immunodominant epitope
(IDE) [42]. The rest of the mapped epitopes can be considered to
be sub-dominant epitopes (SDE) and more than 20 of these induce
easily measurable responses that range from 2–0.2% of CD8+ T
cell at acute times [41]. In the work characterizing the first five
CD8+ T cell epitopes for VACV in C57BL/6, it was noted that
different routes of infection appeared to alter immunodominance
with intradermal (i.d.) infection favoring B820, the IDE, over the
SDE compared to intraperitoneal (i.p.) infection [42]. Responses
to an IDE were also favored by the i.d. route in VACV infections
of BALB/c mice [46]. That this phenomenon was observed in two
strains of mice (with different sets of epitopes) suggests that it was
genuinely linked to immunodominance.
Here we confirm, explore and explain the route-related effects
on CD8+ T cell immunodominance during VACV infection. We
find that immunodominance is linked to the sites of antigen
presentation and that individual draining lymph nodes (LN) are
environments where there is more competition between T cells of
differing specificities than the spleen. Finally we show that the
effects of this competition that occurs after i.d. (but not i.p.)
infection are reduced by a VACV that expresses the costimulators
CD80 and CD86 (B7-1 and 2).
Results
Peripheral routes of infection sharpen
immunodominance
To extend published results suggesting an effect of vaccination
route on CD8+ T cell immunodominance, groups of C57BL/6
mice were infected with 16106 plaque forming units (pfu) vaccinia
virus Western Reserve (WR) strain by i.p., i.d., intravenous (i.v.)
and subcutaneous (s.c.) injection. After 7 days, CD8+ T cell
responses to 15 VACV epitopes (Table 1) were measured using
brief ex vivo stimulation of splenocytes followed by intracellular
staining for IFN-c (ICS) (Figure 1A). This method allows very
accurate enumeration of epitope-specific CD8+ T cells at acute
times after infection [47]. At a broad scale, the overall hierarchy of
the 15 epitopes was similar for the four routes, with B820 being the
IDE and the other 14 epitopes being SDEs. However, on closer
inspection the previously noted increased dominance of the IDE,
B820 over the SDE in i.d. compared with i.p. infected mice was
repeated here. There were statistically significant differences for
several epitopes (including B8) between i.v., i.p. and i.d. routes, but
none differed between i.d. and s.c. infections (statistics not shown).
To see the ratio of IDE to SDE responses more clearly, the data
were plotted to show B820–specific responses as a fraction of the
sum of responses to all epitopes (Figure 1B). When viewed this
way, responses in mice infected by the two peripheral routes (i.d.
and s.c.) had identical IDE:SDE ratios of around 50%, but use of
the systemic i.p. and to a slightly greater extent i.v. route reduced
the dominance of B820 to around 30%. Differences between the
peripheral and systemic routes were statistically significant
(p,0.01). When the data were analyzed to show the total number
of CD8+ T cells responding to each epitope, it could be seen that
summed responses to the subdominant epitopes are reduced when
peripheral routes were used (Figure 1C). The basic phenomenon
of skewing towards B820 after i.d. compared with i.p. infection has
also been observed in memory CD8+ T cell responses, as
measured at 28 days after infection and so is not an artifact of
the acute infection (not shown).
Next we wanted to explore whether this phenomenon was
related to the particular selection of epitopes used or would apply
to other IDE and SDE when expressed as foreign antigens from
VACV. One of the most immunodominant CD8+ T cell epitopes
mapped to date is the gB498–505 epitope (SSIEFARL) of herpes
simplex virus glycoprotein B (HSVgB) and we had two recombi-
nant VACVs expressing this epitope. These express full length
HSVgB (VACVfullgB) or the gB498 epitope as an endoplasmic
reticulum-targeted ‘minigene’ (VACV-ESminigB) [48]. Infection
of mice with these viruses showed that gB498 was a SDE when it
required processing from full HSVgB, but became co-dominant
with B820 when expressed as an ER-targeted minigene (Figure 1D).
Author Summary
During an infection, the adaptive immune system re-
sponds to many epitopes of the pathogen but the
strength of these responses varies widely. This unequal
distribution of responses across a range of epitopes is
known as immunodominance and understanding why it
occurs is a fundamental problem in immunology. It is also
relevant to vectored vaccines where the intention is to
raise immunity against an antigen of choice, but responses
to vector epitopes may dominate. We show that the route
of infection changes the extent to which the strongest
epitope can dominate CD8+ T cell responses to vaccinia
virus (VACV). The cause of this phenomenon is linked to
virus spread and therefore the different lymphoid organs
that prime T cell responses for each route. We also show
that local draining lymph nodes are sites of more robust
competition between T cells compared with the spleen,
explaining why immunodominance differs according to
route. Finally the normally heightened immunodominance
after peripheral VACV infection can be reduced by
expression the costimulators CD80 (B7-1) and CD86 (B7-
2) from the virus. In summary, we have carefully dissected
immunodominance using VACV as a model and in doing
so exposed general features of CD8+ T cell immunity to
pathogens.
Table 1. Synthetic peptides used in this study.
Name Sequence H-2 Gene name
B820 TSYKFESV K
b VACWR190
A8189 ITYRFYLI K
b VACWR127
A3270 KSYNYMLL K
b VACWR122
A23297 IGMFNLTFI D
b VACWR148
K36 YSLPNAGDVI D
b VACWR034
B254 YSQVNKRYI D
b VACWR184
A47138 AAFEFINSL K
b VACWR173
L253 VIYIFTVRL K
b VACWR089
C4125 LNFRFENV K
b VACWR024
J3289 SIFRFLNI K
b VACWR095
A870 IHYLFRCV K
b VACWR127
A4288 YAPVSPIVI D
b VACWR167
G834 LMYIFAAL K
b VACWR086
N260 FLMMNKDEL D
b VACWR029
A1947 VSLDYINTM K
b VACWR139
gB498 SSIEFARL K
b HSV-1 gB
OVA257 SIINFEKL K
b ovalbumin
doi:10.1371/journal.ppat.1003329.t001
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These viruses then provided the opportunity to test the effect of
route of infection on immunodominance using a single epitope
that was either an IDE or a SDE depending on the context. CD8+
T cell responses to the gB498 epitope were then compared to the
sum of responses to all 15 VACV epitopes for the two viruses after
i.d. and i.v. infection. In the context of full HSVgB, where gB498
ranks as an SDE, responses to this epitope were enhanced roughly
two-fold by i.v. compared with i.d. infection, but the opposite
result (albeit with a narrower difference) was obtained for the IDE
minigene version (Figure 1E). Taken together, the conclusion from
these experiments is that VACV infection by peripheral,
compared with systemic routes sharpens immunodominance and
this can predict which route will maximise responses to foreign
antigens expressed from VACV vectors.
Virus dissemination after infection by different routes
VACV has more opportunity to spread after i.p. and i.v.
injection, compared with infection by a peripheral route like i.d.
[49–51]. We reasoned that virus dissemination might be linked to
differences in immunodominance if it affected the range of
secondary lymph organs that have access to virus antigen. To test
the extent to which the inoculated virus spread to lymph organs,
mice were infected by i.d., i.p. and i.v. routes and six hours later,
virus titers were measured in cervical, mediastinal and mesenteric
LNs and spleen (Figure 2A). As expected, after i.v. injection virus
titers were highest in the spleen but virus was also found in each
LN. For i.d. and i.p. routes, the highest titers of virus were in the
cervical and mediastinal LN respectively, which is consistent with
the lymphatic drainage of these injection sites. For i.d. infection,
Figure 1. CD8+ T cell Immunodominance is altered by the route of infection for VACV. (A–C) CD8+ T cell responses to VACV epitopes were
determined in C57BL/6 mice infected with 16106 PFU of VACV WR by i.v., i.p., i.d., or s.c. injection seven days after infection. Data are from two or
more experiments and total mice for each route were: i.v. 8, i.p. 16, i.d. 6 and s.c. 10. A) Means and SEM of percent of CD8+ T cells responding to each
peptide. B) The fraction of all measured responses (sum of responses to all 15 VACV peptides) accounted for by B820-specific (IDE) and the sum of
SDE-specific CD8+ T cells. C) Responses to VACV epitopes broken down into IDE and SDE as in panel B, but shown as total numbers of CD8+IFN-c+
cells per spleen. (D–E) Responses to VACV and HSV gB498 epitopes seven days after infection of mice with 1610
6 PFU of recombinant VACV-fullgB or
VACV-ESminigB. Data are from two experiments with a total of 6 mice per virus. D) Means and SEM of percent of CD8+ T cells responding to each
peptide after i.v. infection (10 of 14 VACV epitopes shown). E) Response to gB498 shown as a fraction of the total measured epitope-specific responses
(VACV+gB498). Selected statistical significance denoted with p value over appropriate bars.
doi:10.1371/journal.ppat.1003329.g001
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spread of inoculum beyond the cervical LN was seen for two of
five mice with low titers found in the spleen. After i.p. infection
virus was found in the spleen in four of five and mesenteric LN in
one of five mice. Next, spread of virus during the first day of
infection was explored by quantifying virus 24 hours after
infection by the same three routes (Figure 2B). At this later time
point virus spread remained wide after i.v. injection (though titers
dropped substantially) and this broad distribution was also seen for
mice infected by the i.p. route. In fact the titers were generally
higher after i.p. compared with i.v. infection. In contrast, virus was
entirely restricted to the cervical lymph node after i.d. infection.
These results demonstrate that there was wider spread of virus and
potential for antigen presentation after i.v. and i.p. than i.d.
infection.
Systemic routes prime CD8+ T cells in more lymphoid
organs early after infection
Having shown wider spread of virus after i.v. and i.p. routes we
wanted to know if this was reflected in the sites where CD8+ T cells
were primed. The first method used was the in vivo cytotoxicity
(CTL) assay, which has been used previously to track sites of T cell
priming [52]. In the first set of experiments, specific killing of B820-
pulsed targets in various lymphoid organs was determined at
different times after i.d. infection (Figure S1 in Supporting
Information). This showed that at two days after i.d. infection,
B820-specific killing activity was already found in the cervical LN,
but it took several more days until it was detected at similar levels
in other LN and spleen, similar to a report with dermal HSV
infection [52]. The killing seen at the other LN and spleen on later
days presumably reflects the recirculation of primed CD8+ T cells
once they leave the site of initial priming. We then examined
killing two days after infection by the i.v. and i.p. routes
(Figure 3A). Two days after infection by the i.v. route, B820-
specific killing was high in all LN and spleen, suggesting priming of
CD8+ T cells in all these sites. Infection by the i.p. route produced
the highest B820-specific killing in the mediastinal LN, but killing
was also strong (around 20%) in spleen and other LN. These data
suggested a difference in the amount of priming at sites beyond the
local draining LN after i.p., compared with i.d. infection and very
widespread priming after i.v. injection.
It was unclear in these experiments if the roughly 10% killing in
the spleen and non-draining LN after i.d. infection was due to the
early migration of some effectors or was background as an artifact
of the assay. To look at the sites of priming even earlier, a
recombinant VACV (NP-S-GFP) expressing the ovalbumin257
(SIINFEKL; OVA257) epitope [53,54] was used in combination
with transferred naive OT-I T cells. The dominance of B820 after
infection of mice with VACV NP-S-GFP by i.v., i.p. and i.d. routes
was similar to that seen for non-recombinant WR (Figure S2 in
Supporting Information). To detect the earliest events of priming
we looked for CD69 up-regulation on the OT-I cells 24 hours
after infection of mice by the three routes (Figure 3B). After i.d.
infection, priming of OT-I T cells, as indicated by CD69 up-
regulation, was very low in all sites other than the cervical LN. In
contrast, i.p. infection primed over 60% of OT-I cells both in the
mediastinal LN and the spleen. As expected, i.v. infection was able
to prime OT-I in all sites. So by this method, priming of CD8+ T
cells at sites beyond the local draining LN is efficient after the
systemic i.v. and i.p. routes, but not the peripheral i.d. route of
infection. While we saw differences in the spread of priming sites, it
remained possible that the length of antigen presentation also
differed and that this might drive changes in immunodominance.
To test this we used the OT-I model again, but this time did
transfers at various times after infection (day 1, 3 and 5) by i.d. or
i.v. route and looked for CD69 up regulation 24 hours later
(Figure 3C). Overall, there was no difference in kinetics of
presentation between the routes and priming of OT-I was
observed on all days, though it began to wane at the latest time
(day 5 to 6). However, we were surprised to see that priming in the
spleen was relatively poor at all times after i.v. infection in this
experiment, which was in contrast to findings earlier after infection
(Figure 3B). To ensure that this was sound, an experiment was
done to include a day 1 readout of OT-I activation side-by-side
with later times after i.v. infection and this confirmed that priming
in the spleen declines more rapidly than in LN (not shown).
Interestingly, by day 3–4, there is little difference in priming in the
spleen between the i.v. and i.d. infected mice. All together these
experiments show that a difference between the systemic and
peripheral routes is the extent to which antigen spread allows
CD8+ T cell priming to take place at early times in lymphoid
organs beyond the LN and perhaps especially in the spleen.
Reduced immunodominance is associated with robust
priming in the spleen
Next we wanted to explore whether the number of priming sites
and/or levels of presentation lead to reduced immunodominance.
First, peripheral routes were explored and priming in more LN
Figure 2. VACV spreads more widely after i.v. or i.p. infection.
C57BL/6 mice were infected with 16106 PFU of VACV WR by i.v., i.p. or
i.d. injection. At 6 (A) or 24 (B) hours after infection, spleen and lymph
nodes were collected and infectious virus measured by plaque assay.
Titers from each organ are plotted with the average for each group
shown by a grey bar. The dotted line represents the limit of detection (3
PFU/Organ).
doi:10.1371/journal.ppat.1003329.g002
Immunodomination in Virus Infection
PLOS Pathogens | www.plospathogens.org 4 April 2013 | Volume 9 | Issue 4 | e1003329
was achieved by simultaneous injections (two i.d. and two s.c.) at
four different sites. Seven days later, responses to the panel of 15
VACV peptides were determined. In mice that received these
multiple concurrent injections, responses to the VACV epitopes
were similar to those in mice infected at a single site, with B820–
specific CD8+ T cells accounting for 50% of the total epitope-
specific response (Figure 4A and compare with Figure 1B and C).
This suggested that if priming was restricted to LN, increasing the
number of lymphoid organs where priming occurs does not reduce
immunodominance. In the second experiment, the dose of virus
given was reduced to 16103 PFU, which we reasoned would stop
the spread of virus to the spleen after i.p. injection and also greatly
limit the number of APCs irrespective of route. First, VACV NP-
S-GFP and OT-I transfer was used to directly examine sites of
priming after this low-dose infection (Figure 4B). At 24 hours after
i.p. infection, only modest priming (5% of OT-I activated) was
observed with this dose and it was exclusively in the mediastinal
LN. When a similar low dose was used by the i.v. route, again
priming was poor (10% of OT-I), but in this case it was found only
in the spleen. Therefore the reduced dose clearly limited the
spread of antigen and the levels of presentation. Next we examined
the effect of this reduced dose on immunodominance and found
that mice infected with a low-dose by the i.p. or i.v. routes had
CD8+ T cell responses more heavily dominated by the IDE, which
now accounted for 50% and 60% of the epitope-specific response
respectively (Figure 4C). This is similar, if not more extreme
domination by B820 as seen for i.d. infection at the standard high
dose. By contrast, reducing the dose to 16103 PFU in i.d. infection
did not further sharpen immunodominance for this route. The
lower dose given by all routes resulted in much lower total
numbers of epitope-specific CD8+ T cells and again in the case of
i.p. and i.v. routes it was SDE-specific responses that were most
reduced (Figure 4D). For example reducing dose in the i.v. route
roughly halved the number of B820-specific CD8
+ T cells, but
reduced the number of SDE-specific T cells by around three
quarters. In case the dose changed the kinetics of response for the
various epitopes, the immunodominance hierarchy was examined
at days 6, 7, 8, 9 and 11 after i.p. infection and the dominance of
B820 was remarkably stable across these five times (Figure S3 in
Supporting Information). From these data it was concluded that
simply increasing the number of lymph organs where priming
occurs does not reduce immunodominance, neither does priming
in the spleen guarantee this outcome. Rather, only where priming
in the spleen is substantial can immunodominance be reduced.
This suggests a requirement for a higher number of APCs being
involved in priming in one organ (as offered by the spleen), rather
than there being a special property of splenic versus LN APCs.
Immunodomination is greater after peripheral infection
The results thus far suggested that the sharpened immunodo-
minance after i.d. infection could be due to a limiting resource
needed for priming (e.g. number of APCs) in LN and therefore
greater potential for immunodomination. To examine immuno-
domination directly, cross competition between transferred OT-I
cells responding to OVA257 expressed from VACV NP-S-GFP
and endogenous CD8+ T cells responding to the VACV epitopes
was examined. This approach was originally used to examine
competition between T cell clones for OVA257, but OT-Is can also
cross-compete with native virus epitopes co-expressed with
OVA257 [38,55]. Two doses (1610
3 and 16105) of congenically
marked OT-I T cells (CD45.2+) were transferred into B6.SJL mice
(CD45.1+), which were infected with VACV NP-S-GFP a day
later. After seven days, splenic responses to the set of 15 VACV
peptides (CD45.1+) and the number of responding OT-I T cells
Figure 3. Wider spread but not longevity of antigen presen-
tation is associated with systemic routes. A) Cytotoxicity in
lymphoid organs of mice infected with 16106 PFU of VACV WR by the
routes shown was determined by measuring the specific lysis of B820
epitope–pulsed splenocytes two days after infection. Data are from two
or more experiments and total mice for each route were: i.d. 7, i.p. 9 and
i.v. 7. Killing in the spleen was significantly lower for i.d. compared with
i.p. (p,0.05) or i.v. (p,0.01) infected mice. B) B6.SJL mice were given
56106 OT-I CD8+ T cells (CD45.2+), then the following day infected with
16106 PFU of VACV NP-S-GFP by the routes shown. At 24 hours post-
infection, expression of CD8, CD45.2 and CD69 were measured by flow
cytometry on cells from spleens and LNs. Mean and SEM of percent of
OT-I CD8+ cells expressing CD69 is shown. Data are from two or more
experiments and total mice for each route were: i.d. 5, i.p. 5 and i.v. 3.
Priming of OT-I in the spleen was significantly (p,0.05) lower for i.d.
compared with i.p. (p,0.01) or i.v. (p,0.001) infected mice. C) B6.SJL
mice were infected with 16106 PFU of VACV NP-S-GFP by the routes
shown then given 56 106 OT-I CD8+ T cells (CD45.2+) 1, 3 and 5 days
later. Expression of CD8, CD45.2 and CD69 were measured by flow
cytometry on cells from spleens and LNs 24 hours after transfer to give
times 2, 4 and 6 as shown on the graph. Means and SEM of percent of
OT-I CD8+ cells expressing CD69 are shown.
doi:10.1371/journal.ppat.1003329.g003
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(CD45.2+) were measured by ICS. This experiment was done with
mice infected by the i.d. route and the i.v. route to represent the
greatest and least domination by B820 in the experiments shown
thus far. When data were analyzed either as a percent of CD8+ T
cells (Figure 5A) or as total number of CD8+ T cells (Figure 5B),
responses to VACV epitopes were significantly reduced by the
presence of competing OT-I T cells after i.d., but not i.v. infection.
This is despite the relatively larger expansion of the transferred
OT-I cells in i.v. infected mice. No significant suppression of
VACV-specific responses by OT-I transfer was seen when mice
were infected with a control virus that did not express the OVA257
peptide (Figure S4 in Supporting Information). It was possible that
the transfer of so many OT-I cells might influence the amount of
virus growth and therefore antigen presentation during i.d.
infection. This was tested by removing the ears from i.d. infected
mice that had received OT-I or no transferred cells and
Figure 4. Immunodominance is reduced by robust priming in the spleen. A) CD8+ T cell responses to 15 VACV epitopes were measured by
intracellular staining of IFN-c seven days after infection with 16106 PFU of VACV WR in total spread equally across four peripheral sites (left and right
ear pinnae, i.d. and shanks, s.c.). The fraction of the total measured response accounted for by the IDE-specific and the sum of SDE-specific CD8+ T
cells is shown on the left. On the right, responses are again broken down into IDE and SDE, but shown as total numbers of CD8+IFN-c+ cells per
spleen. Mean and SEMs of 5 mice from two experiments are shown. B) Priming of OT-I CD8+ T cells as demonstrated by upregulation of CD69
expression in the lymphoid organs shown 24 hours after infection with 16103 PFU (low dose) of VACV NP-S-GFP by i.v. or i.p. injection (as for
figure 3B). Data are from more than two experiments; 4 mice for i.p. and 3 for i.v. route. C-D) CD8+ T cell responses to 15 VACV epitopes in mice
infected with 16103 or 16106 PFU of VACV WR by the routes shown, as described previously. Data are from more than one experiment and numbers
of mice were: i.v. 106 = 3, 103 = 7; i.p. 106 = 5, 103 = 18; i.d. 106 = not done (N.D.), 103 = 11. C) Data shown are the fraction of the total measured
response accounted for by the IDE-specific and the sum of SDE-specific CD8+ T cells. D) Responses are again broken down into IDE and SDE, but
shown as total numbers of CD8+IFN-c+ cells per spleen. Statistical significance denoted with p value over appropriate bars.
doi:10.1371/journal.ppat.1003329.g004
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determining virus titers by plaque assay. There was no difference
in the amount of infectious virus found in ears of mice that
received OT-I cells, compared with controls (Figure 5C). Together
these data suggest that CD8+ T cell responses are more prone to
immunodomination after i.d., compared with i.v. infection.
Costimulation reduces immunodominance after i.d. but
not i.p. infection
Immunodomination is most likely the result of T cells
competing for limited resources on or very close to APCs, but
none have been identified. One essential resource required for
CD8+ T cell priming that has been proposed, but not shown to be
involved in immunodominance is costimulation [56–58]. These
studies used mice deficient in CD28 or treated mice with soluble
reagents that block the interaction between CD28 and the
costimulators CD80 (B7-1) and CD86 (B7-2). However, this
approach only tests the effect of eliminating costimulation and so
cannot reveal whether costimulation under normal conditions can
be limiting and might be a resource for which CD8+ T cells
compete. To test this possibility, we used a recombinant VACV
expressing CD80 and CD86 (VACV-CD80&86) and infected
mice by the i.d. and i.p. routes. Priming of CD8+ T cells by VACV
is thought to be largely via direct presentation, so this virus should
increase the amount of costimulation available on each APC
[53,59,60]. Consistent with a role for limiting CD80 and CD86
playing a role in immunodomination, mice infected i.d. with
VACV-CD80&86 had higher responses to SDEs and the ratio of
IDE to SDE was significantly lower than in mice infected with the
control VACV (Figure 6). By contrast, in the i.p. infected mice
there was no enhanced response to any epitope and immunodo-
minance was unaltered. Further when analyzed by total number of
VACV-specific CD8+ T cells, in mice infected by the id. but not
i.p. route expression of CD80 and CD86 improved the sum of
responses to SDEs, but not to B820. From these results we
conclude that expression of costimulators by a recombinant
VACV reduces immunodomination.
Discussion
Infection route has been suggested to alter several aspects of
CD8+ T cell responses to a variety of viruses including priming
mechanism, magnitude and quality [61–65]. Here we demonstrate
clearly that for VACV, immunodominance also needs to be
considered. This leads to the first important conclusion of this
work, which is that where magnitude of response is a primary
read-out, examining responses to a single epitope can be
misleading. For example, if B820 was used as a sole epitope in
the experiment shown in Figure 1A, one would conclude that i.d.
or s.c. injections of VACV were most immunogenic. In contrast if
the majority of the SDE were chosen, the opposite conclusion
would be drawn. The size of differences in response for individual
SDE varied, but were up to four-fold for C4125 across the routes.
Analyzing the total number of epitope-specific CD8+ T cells
removes the apparent improvement of B820-specific response seen
by the peripheral routes, but makes the suppressive effect of these
routes on the SDE more pronounced, with the difference for C4125
being more than seven-fold. So while as an overall picture, the
change in dominance profile across the doses seems quite modest
compared with the very big differences in virus spread and
Figure 5. Greater cross-competition from transferred OT-I cells
after peripheral infection. A–B) B6.SJL mice were infected with
16106 PFU of VACV NP-S-GFP by i.d. or i.v. injection a day after
receiving the numbers of OT-I CD8+ T cells as shown. Seven days later,
CD8+ T cell responses to 15 VACV epitopes plus OVA257 were measured
by intracellular staining of IFN-c. OT-I T cells were identified by
expression of CD45.2. CD8+ T cells responding to VACV (as a sum of all
15 peptides) and OT-I CD8+ T cells responding to OVA257 are show as a
percent of all CD8+ T cells (A) and as a total number of CD8+ IFN-c+ cells
per spleen (B). Graph shows the average 6 SEM and data come from
two independent experiments and a total of at least 4 mice for each
route and dose of OT-I cells. Statistical significance denoted with p
value over appropriate bars. C) B6.SJL mice that received the number of
OT-I CD8+ cells as shown were infected with 16106 PFU of VACV NP-S-
GFP i.d.. On day 5 and 7 post-infection, virus titers in the ear pinnae
were determined by plaque assay. Data are titers from individual ears
and the grey bar represents the average.
doi:10.1371/journal.ppat.1003329.g005
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Figure 6. Immunodominance in i.d. but not i.p. infected mice was reduced by over-expression of CD80 and CD86. CD8+ T cell
responses to VACV epitopes were determined in C57BL/6 mice infected i.d. with 16104 PFU of VACV-CD80&86 or control virus (VSC-8) or i.p. with
16106 PFU of the same viruses. Seven days later, CD8+ T cell responses to 15 VACV epitopes were measured by intracellular staining of IFN-c. Data are
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number of priming sites, effects were substantial for some
individual epitopes. Much VACV immunology in the past has
used recombinant viruses and responses to a single foreign epitope
were monitored. In the light of our results some conclusions from
these earlier experiments may need to be reconsidered. Indeed the
experiments shown here with HSVgB498 demonstrate that
different forms of antigen can change the dominance ranking of
an epitope dramatically in the context of a recombinant VACV.
This in turn alters its competitiveness as an immunogen
differentially according to route. There are also lessons here for
studies of immunodominance using other viruses where few
epitopes are known or used.
The original experiments that indicated a role for route in
VACV immunodominance used only dermal scarification and i.p.
routes [42]. By including i.v. and s.c. routes here, the association
between virus spread and immunodominance was noted and then
confirmed virologically. The lack of spread after i.d. infection was
not surprising [49]. However, the much larger amount of virus
found in all organs 24 hours after i.p., compared with i.v. injection
was less expected. The reduction in virus in all lymph organs from
6 hrs to 24 hrs after i.v. injection suggests that these sites do not
sustain VACV replication. Therefore the higher amounts of virus
found a day after i.p. injection are most likely the result of
continued draining of virus generated at other sites, rather than
infection of the lymph organs. This is an advantageous feature of
the VACV model in that findings made in lymph organs are not
complicated by these also being major sites of virus infection. In
terms of CD8+ T cell immunity, presence of any virus in lymphoid
organs was a useful a guide for defining priming sites, even if the
amounts measured were poorly predictive of antigen presentation
levels. For example, despite very low levels of infectious virus being
found in the various LN after i.v. infection, priming was robust at
all these sites. Perhaps in this situation many APCs are reached by
the ample (16106 PFU) inoculum and despite undergoing abortive
infections, these cells persist long enough to prime effectively.
Alternatively there may be a reservoir of antigen that is cross
presented, but the evidence thus far suggests that direct priming is
more important for VACV-specific CD8+ T cells [60]. The
kinetics of antigen presentation as determined for the i.d. and i.v.
routes were remarkably similar with sustained activation of OT-I
cells seen until day 5–6, though it was decreasing by this time. This
result rules out the premature loss of antigen presentation in LN,
perhaps as a result of killing of APCs by IDE-specific T cells, as a
mechanism for increased immunodominance associated with the
i.d. route. Further the one organ where presentation seemed to
decay the fastest was the spleen after i.v. infection and antigen
presentation levels there became very similar for i.d. and i.v. routes
by day 3–4. This points to early antigen presentation events being
more important in setting the immunodominance hierarchy,
possibly reflecting the requirement for only a brief encounter with
antigen to drive CD8+ T cell responses [66,67].
We considered the possibility that there was something
qualitatively different between the APCs in the spleen and LN
that leads to reduced immunodominance. If this were correct,
reduced immunodominance should be the hallmark of any
responses primed in the spleen. However, reducing virus dose by
i.v. and i.p. routes and thereby restricted priming to the spleen and
a LN respectively, sharpened immunodominance in both cases.
On the other hand, the lower doses also greatly limited the
number of APCs available at any priming site, as demonstrated by
poor priming of OT-I cells. Strikingly, restricting priming to the
mediastinal LN with low dose i.p. infection lead to exactly the
same ratio of IDE:SDE as found for any dose of virus injected i.d.
where priming also occurs in a single LN. Further, increasing the
number of LNs involved in priming and thereby total APC
numbers by infecting multiple peripheral sites did not reduce
immunodominance. To reduce immunodominance, a large
number of APCs in a single lymph organ were required and this
was only provided by the spleen when there was an abundance of
antigen. Finally, reducing the virus dose given i.d. did not further
sharpen immunodominance, which together with other results
here suggests there is a limit to immunodomination. We speculate
that the architecture and size of LNs limit APCs and/or some
associated essential resources required for priming over a wide
range of antigen doses and increase competition between T cells.
The possibility of a more competitive environment in LN was
confirmed by subjecting VACV-specific CD8+ T cells to rivalry
from transferred OT-I T cells. The finding that VACV responses
were more easily suppressed by OT-I after i.d. but not i.v.
infection is consistent with greater competition across specificities
when priming is restricted to LN. This leads to the conclusion that
immunodomination in LNs, which are the main priming sites after
i.d. infection, suppresses responses to SDE.
Having established i.d. infection with VACV as a setting where
immunodomination can occur in primary responses, we decided to
take advantage of this model to examine the role of costimulation
in immunodominance. Our data suggest that increasing levels of
costimulators to APCs that directly prime CD8+ T cells in a LN
reduces the level of immunodomination by the IDE. Conversely,
there was no advantage for SDE (or the IDE) when these
constimulators were expressed by a virus given by the i.p. route.
This effect for the i.d. route might be achieved either by reducing
competition for costimulation on individual APCs or possibly
extending the number of APCs that have adequate levels of
costimulators to prime CD8+ T cells. Several groups have
demonstrated that CD8+ T cell responses can occur in the
absence of costimulation via CD80/CD86 and CD28, but that
these responses are substantially compromised [58,68–71]. The
only report to examine multiple epitopes came to the conclusion
that costimulation affected IDE and SDE equally [58]. This is not
necessarily inconsistent with our findings or conclusions. We are
not suggesting that IDE and SDE have a differential requirement
for costimulation, but rather that in the context of priming in LNs,
costimulation is limiting and IDE have an advantage in competing
for this resource. The VACV strains that express CD80 and CD86
used here were originally developed to be improved vaccine
vectors [72]. Other reports with similar viruses suggest that they
enhance magnitude and avidity of CD8+ T cell responses to model
antigens that are co-expressed from the same virus [73,74]. While
we have not tested avidity, our data on magnitude are consistent
with these published reports: the epitopes examined previously
would rank as SDE and the immunizations published were done
using a peripheral route (s.c.). However, the assumption made
until now was that all CD8+ T cell responses could be boosted by
expression of the costimulators. Here we show that the benefit of
expressing costimulators, at least in terms of magnitude of response
from two experiments and a total of 8 and 6 mice per virus for i.d. and i.p. respectively; route is shown above each graph. A) Means and SEM of
percent of CD8+ T cells responding to each peptide. * p,0.05, ** p,0.01. B) The fraction of all measured responses accounted for by B820-specific
(IDE) and the sum of SDE-specific CD8+ T cells. Statistical significance denoted with p value over appropriate bars. C) Responses to VACV epitopes
broken down into IDE and SDE as in panel B, but shown as total numbers of CD8+IFN-c+ cells per spleen.
doi:10.1371/journal.ppat.1003329.g006
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may be for SDE only. This reinforces again the importance of
examining responses to multiple epitopes before drawing conclu-
sions about the benefit of different immunization strategies based
on pre-clinical models in mice.
In conclusion, we show here that route-related changes in
immunodominance after primary infection with VACV are the
result of differential spread of virus antigen, which determines the
sites of CD8+ T cell priming. CD8+ T cell priming is more
competitive when it is mainly limited to LNs and consequently
subdominant specificities are subject to greater immunodomina-
tion at these sites. Further, we identify costimulatory molecules as
one of the resources that might be limited in LN and therefore
drive immunodomination. These data have implications for the
interpretation of preclinical vaccinology of vectored vaccines.
Beyond these insights this work has ramifications for viral
immunology in general, demonstrating clearly the importance of
putting responses to any single epitope into the broader context of
responses to the whole virus.
Materials and Methods
Viruses and cell lines
The majority of viruses used here were kind gifts: WR (Bernard
Moss, NIH); VACV NP-S-GFP [54,75], WR B7-1&B7-2 (called
VACV-CD80&86 here) [72] and VSC-8 (as a TK2 control virus
for VACV-CD80&86) (Jon Yewdell and Jack Bennink, NIH);
VACV-ESminigB [48] (S. Tevethia, Penn State Medical College).
VACV-fullgB was made by standard homologous recombination
methods using plasmid pSC11 [76] to insert the full coding
sequence of HSVgB under the control of the p7.5 promoter into
the thymidine kinase gene of VACV WR. All recombinant
antigens in viruses used here were expressed by the p7.5 promoter
from a disrupted thymidine kinase gene of strain WR. Immortal-
ized cell lines, BHK-21 and BS-C-1, were maintained in
Dulbecco’s Modified Eagle medium (DMEM, Invitrogen) with
glutamine and 10% or 2% fetal bovine serum (FBS). VACVs were
grown in BHK-21 and purified by centrifugation through a 36%
sucrose cushion, then infectivity was titrated on BS-C-1 cells using
standard methods.
Ethics statement
All experiments were done according to Australian NHMRC
guidelines contained within the Australian Code of Practice for the
Care and Use of Animals for Scientific Purposes and under
approvals F-BMB-38.8 and A2011-01 from the Australian National
University Animal Ethics and Experimentation Committee.
Mice and infections
Specific pathogen-free C57BL/6, B6.SJL and OT-I transgenic
mice were obtained from the Animal Resource Centre (Perth,
Australia) and APF (Canberra, Australia). Unless stated, mice were
infected with 16106 PFU of VACV by i.p., i.v. or s.c. in 200 ml of
PBS or by i.d. [77] in 5 or 10 ml of PBS.
Stimulation with peptides and intracellular cytokine
staining
Mice were euthanized 7 days after infection and spleens were
taken for analysis of CD8+ T cell responses by intracellular
cytokine staining (ICS) as described previously [47]. Briefly,
splenocytes were plated at 16106 cells/well into round-bottom 96-
well plates. Synthetic peptides (Table 1) were added to a final
concentration of 1027 M and plates were incubated at 37uC with
5% CO2. After 1 hour, 50 mg/ml brefeldin A (Sigma-Aldrich, St.
Louis, MO) was added. Plates were incubated for another 3 hours,
then spun at 4uC to remove the medium. Cells were resuspended
in 40 ml of 1/150-diluted anti-CD8-PE antibody (clone 53-6.7; BD
Biosciences, San Jose, CA). After 30 min incubation on ice, cells
were washed, resuspended in 50 ml of 1% paraformaldehyde, and
incubated at room temperature for 20 min. After two washes, cells
were stained with 40 ml of 1/200-diluted anti-IFN-c allophyco-
cyanin antibody (clone XMG1.2; BD Biosciences) with 0.25%
saponin (Sigma-Aldrich) overnight at 4uC. Cells were washed
three times before acquisition using a FACS LSRII (BD
Biosciences). Analysis was done in Flowjo software (Tree Star,
Ashland, OR). Events were gated for live lymphocytes on forward
scatter (FSC)6 side scatter (SSC), followed by CD8+ cells6 IFN-
c. Backgrounds as determined for samples without peptide were
usually in the order of 0.1–0.2% and were subtracted from the
values presented for test samples.
Virus titration by plaque assay
Organs harvested from infected mice were homogenized in 1 ml
glass homogenizers (Wheaton) then rapidly frozen and thawed 3
times in liquid nitrogen and a 37uC water bath. The homogenized
organs were then 10-fold serial diluted in DMEM with 2% FBS
before adding to the 6-well plates with BS-C-1 cell monolayer. After
90 min of incubation at 37uC with 5% CO2, the virus inoculates were
removed and replaced by 2 ml/well of 0.4% Sodium carboxymethyl
cellulose (CMC, Sigma-Aldrich) in DMEM with 2% FBS. Plates
were incubated at 37uC with 5% CO2 for 3 days, then crystal violet
(Sigma-Aldrich) used to stain. Plaques were counted and virus titers
were determined according to the dilution factor.
In vivo T cell activation and CD69 staining
CD8+ T cells were prepared from the spleens and lymph nodes
of naive OT-I mice using magnetic bead-based negative selection
(Miltenyi), and resuspended in PBS with 2% FBS for i.v. transfer.
Each B6.SJL mouse received about 56106 OT-I CD8+ T cells
and rested for .18 hours. 24 hours after infection with 106 PFU
of VACV NP-S-GFP by various routes, these infected and naive
mice were sacrificed. Single cell suspensions were made from the
spleens and lymph nodes, and stained with anti-CD8-PE antibody
(clone 53-6.7; BD Biosciences, San Jose, CA), anti-CD45.2-APC
antibody (clone 104; BioLegend, San Diego, CA) and anti-CD69-
PE-Cy7 (clone H1.2F3; BD Biosciences, San Jose, CA) before
acquiring by FACS LSRII (BD Biosciences). The activation of
OVA-specific T cells is determined by CD69 expression on
CD45.2+CD8+ cells.
In vivo cytotoxicity assay
Target cells for cytotoxicity detection were prepared from naive
C57BL/6 mice and split into two populations for peptide-pulsing
with B820 and SIINFEKL respectively at 37uC for 1 hour. These
two populations were then labeled with different concentration of
CFSE (Sigma-Aldrich), 9 mM for B820 (CFSE
Hi) and 0.9 mM for
SIINFEKL (CFSELo), before mixing equal number of cells together
for i.v. transfer. A total of 26107 cells were injected into each mouse
which was infected with 16106 PFU of VACV WR for days as
described. After 4 hours, the mice were sacrificed for their spleens
and lymph nodes. The cell numbers in two CFSE-positive
populations were acquired by FACS LSRII (BD Biosciences) for
analysis. The specific lysis was calculated by the following formula:
[12(CFSELo/CFSEHi)naive/(CFSE
Lo/CFSEHi)infected]6100.
Statistical analysis
Unless stated otherwise, statistical comparisons were done using
an unpaired t test with Welch’s correction because populations
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had unequal variance. All tests were analyzed with the aid of
GraphPad Prism software (GraphPad, La Jolla, CA).
Supporting Information
Figure S1 Time course of cytotoxicity in LN and spleen
after i.d. infection. C57BL/6 mice were i.d. injected with
16106 PFU of VACV WR, and in vivo cytotoxicity in lymphoid
organs were determined on designated days post-infection by
measuring the specific lysis of B820 peptide-pulsed splenocytes.
Graph shows the average 6 SEM; data are from more than two
experiments and three or more mice for each time point. Statistical
significance was determined by unpaired Student’s t-test.
(TIF)
Figure S2 Similar immunodominance was observed
after infection with VACV NP-S-GFP via various routes.
CD8+ T cell responses to 15 VACV epitopes in C57BL/6 mice
infected with 16106 PFU of VACV NP-S-GFP were determined
by intracellular staining of IFN-c. Graph shows the fraction of all
measured responses (sum of responses to all 15 VACV peptides)
accounted for by B820-specific (IDE) and the sum of SDE-specific
CD8+ T cells. Data are from two experiments and total mice for
each route were: i.v. 6, i.p. 9 and i.d. 6.
(TIF)
Figure S3 Immunodominance was maintained through
the course of infection. CD8+ T cell responses to VACV
epitopes B820, A8189, K36 and B254 in C57BL/6 mice injected i.p.
with 16103 PFU of VACV WR were determined as previously
described on designated day after infection. Graph shows the
mean and SEM of the fraction of the total measured response
accounted for by B820–specific CD8
+ T cells. Data are from 3
mice per group on each day, except for day 6 (marked with #)
where only 1 of 3 mice had detectable responses to any peptide.
(TIF)
Figure S4 No significant suppression of VACV-specific
responses by OT-I in the absence of OVA257 expression.
After being transferred with designated numbers of OT-I CD8+ T
cells and rested for overnight, B6.SJL mice were infected with
16106 PFU of control virus VSC-8, which does not express
OVA257. Seven days later, CD8
+ T cell responses to 15 VACV
epitopes plus OVA257 were measured by intracellular staining of
IFN-c. Graph shows the average6 SEM of sum of VACV-specific
responses in percent of CD8+ cells (left) or total number of CD8+
cells per spleen (right).
(TIF)
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